<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294644</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-101-10-17</org_study_id>
    <secondary_id>2010-020691-28</secondary_id>
    <nct_id>NCT01294644</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat</brief_title>
  <official_title>Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kythera Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kythera Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of
      submental fat (fat below the chin).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>A CR-SMFRS response is defined as at least a 1-point improvement (i.e. 1-point reduction) from Baseline 12 weeks after the last treatment.
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Subject Self Rating Scale (SSRS) Response</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>A SSRS response is defined as an SSRS score that is 4 or greater 12 weeks after the last treatment.
The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a CR-SMFRS 2-grade Response</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>A CR-SMFRS 2-grade response is defined as at least a 2-point improvement (i.e. 2-point reduction) from Baseline 12 weeks after the last treatment.
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CR-SMFRS Score</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.
A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SSRS Scores</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.
A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Submental Fat Thickness</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>Submental thickness was measured using caliper devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you currently have under your chin?&quot; answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. Improvement is defined as any decrease in score and worsened as any increase in score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>The PR-SMFIS assesses the impact of submental fat on self-perception of 6 characteristics related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Self-rating of Attractiveness</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
    <description>Self-rating of attractiveness assesses aspects of appearance from the participant's perspective by a series of 6 questions:
How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?&quot; Each question was answered on a scale from 1 to 9 where 1 = Not at all attractive, 5 = Neither attractive nor unattractive and 9 = Extremely attractive.
A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Derriford Appearance Scale 24 (DAS24)</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Image Quality of Life Inventory (BIQLI)</measure>
    <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Moderate or Severe Submental Fullness</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deoxycholic Acid Injection 1 mg/cm²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deoxycholic Acid Injection 2 mg/cm²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deoxycholic acid injection</intervention_name>
    <arm_group_label>Deoxycholic Acid Injection 1 mg/cm²</arm_group_label>
    <arm_group_label>Deoxycholic Acid Injection 2 mg/cm²</arm_group_label>
    <other_name>ATX-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate buffered saline placebo for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Submental fat graded by the investigator as 2 or 3 using the Clinician-Reported
             Submental Fat Rating Scale (CR-SMFRS) as determined on Visit 2.

          2. Dissatisfaction with the submental area rated by the subject as 0, 1, 2, or 3 using
             the Subject Self Rating Scale (SSRS).

          3. Males and nonpregnant, nonlactating females between 18 and 65 years of age, inclusive
             on the day of randomization. Females of childbearing potential must have a negative
             human chorionic gonadotropin (hCG) test result within 28 days before randomization and
             agree to practice medically acceptable birth control during the course of the study.
             Medically acceptable birth control includes: surgical sterilization, hormonal
             contraceptives, barrier methods or an intrauterine device (IUD).

          4. History of stable body weight, in the judgment of the investigator, for at least 6
             months before randomization. No significant change, in the judgment of the
             investigator, in diet or exercise practices for at least 6 months before randomization
             and agreement to not change diet or exercise practices during the course of the study.

          5. Expected to comply with and understand the visit schedule and all protocol-specified
             tests and procedures.

          6. Medically able to undergo the administration of study material determined by clinical
             evaluations made within 56 days before and laboratory tests obtained within 28 days
             before randomization for which the investigator identified no clinically significant
             abnormality.

          7. Signed informed consent obtained before any study-specific procedure is performed.

        Exclusion Criteria:

          1. History of any intervention to treat submental fat (e.g., liposuction, surgery, or
             lipolytic agents) or trauma associated with the chin or neck areas, which in the
             judgment of the investigator may affect evaluation of safety or efficacy of treatment.

          2. Loose skin in the neck or chin area for which reduction in submental fat may, in the
             judgment of the investigator, result in an aesthetically unacceptable outcome or a
             score of 4 on the Skin Laxity Rating Scale (SLRS).

          3. Prominent platysmal bands at rest or other anatomical features that, in the judgment
             of the investigator, may interfere with the evaluation of submental fat or result in
             an aesthetically unacceptable outcome.

          4. Evidence of any cause of enlargement in the submental area (e.g., thyroid enlargement
             or cervical adenopathy) other than localized submental fat.

          5. Body mass index (BMI) greater than 30.

          6. Currently on or considering starting a weight reduction regimen.

          7. Any medical condition (e.g., respiratory, cardiovascular, hepatic, neurological
             disease, uncontrolled hypertension, or thyroid dysfunction) that would interfere with
             assessment of safety or efficacy or compromise the subject's ability to undergo study
             procedures or provide informed consent.

          8. Treatment with radio frequency, laser procedures, chemical peels, or dermal fillers in
             the neck or chin area within 12 months before randomization, or botulinum toxin
             injections in the neck or chin area within 6 months before randomization.

          9. History of sensitivity to any components of the study material or to topical or local
             anesthetics (e.g., lidocaine, benzocaine, or novocaine).

         10. Previous randomization into this study or previous treatment with ATX-101.

         11. Treatment with an investigational device or agent within 30 days of randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Beddingfield, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kythera Biopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Geel</city>
        <zip>2440</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75116</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Recklinghausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10827</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Monchengladbach</city>
        <zip>41236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Münster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28043</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B74 2UG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF10 2GF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W1G 8SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Loughborough</city>
        <zip>LE11 1TZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <results_first_submitted>May 28, 2015</results_first_submitted>
  <results_first_submitted_qc>May 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 12, 2015</results_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 29 study centers in the European Union.</recruitment_details>
      <pre_assignment_details>The study consisted of a 12-week treatment period and a 12-week safety follow-up period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Deoxycholic Acid Injection 1 mg/cm²</title>
          <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
        </group>
        <group group_id="P2">
          <title>Deoxycholic Acid Injection 2 mg/cm²</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous Reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Deoxycholic Acid Injection 1 mg/cm²</title>
          <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
        </group>
        <group group_id="B2">
          <title>Deoxycholic Acid Injection 2 mg/cm²</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="114"/>
            <count group_id="B4" value="354"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="10.21"/>
                    <measurement group_id="B2" value="45.9" spread="9.95"/>
                    <measurement group_id="B3" value="46.1" spread="9.50"/>
                    <measurement group_id="B4" value="46.0" spread="9.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 - 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.69" spread="10.892"/>
                    <measurement group_id="B2" value="75.60" spread="10.913"/>
                    <measurement group_id="B3" value="74.62" spread="11.879"/>
                    <measurement group_id="B4" value="75.32" spread="11.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.26" spread="2.709"/>
                    <measurement group_id="B2" value="26.53" spread="2.673"/>
                    <measurement group_id="B3" value="26.06" spread="2.550"/>
                    <measurement group_id="B4" value="26.29" spread="2.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>Fitzpatrick Skin Type is a numerical classification schema for human skin color and typical response to ultraviolet (UV) light:
Type I: Pale white skin, blue/hazel eyes, blond/red hair; Always burns, does not tan.
Type II: Fair skin, blue eyes; Burns easily, tans poorly.
Type III: Darker white skin; Tans after initial burn.
Type IV: Light brown skin; Burns minimally, tans easily.
Type V: Brown skin; Rarely burns, tans darkly easily.
Type VI: Dark brown or black skin; Never burns, always tans darkly.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV-VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response</title>
        <description>A CR-SMFRS response is defined as at least a 1-point improvement (i.e. 1-point reduction) from Baseline 12 weeks after the last treatment.
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <population>Intent-to-treat (ITT) population which included all randomized participants who had at least one efficacy assessment (CR-SMFRS or Subject Self Rating Scale) at Baseline. Last observation carried forward (LOCF) method was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid Injection 1 mg/cm²</title>
            <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
          <group group_id="O2">
            <title>Deoxycholic Acid Injection 2 mg/cm²</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response</title>
          <description>A CR-SMFRS response is defined as at least a 1-point improvement (i.e. 1-point reduction) from Baseline 12 weeks after the last treatment.
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.</description>
          <population>Intent-to-treat (ITT) population which included all randomized participants who had at least one efficacy assessment (CR-SMFRS or Subject Self Rating Scale) at Baseline. Last observation carried forward (LOCF) method was used to impute missing data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="62.3"/>
                    <measurement group_id="O3" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was there was no difference between deoxycholic acid 1 mg/cm² and placebo.
An adjustment for multiplicity was performed for the two co-primary endpoints. This was accounted for by using the larger of the two P-values in the Bonferroni-Holm scheme.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression analysis with treatment and Baseline CR-SMFRS value in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>4.43</ci_upper_limit>
            <estimate_desc>The odds ratio was based on a logistic regression model adjusted for the Baseline score. Odds ratios &gt;1 indicate a positive treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was there was no difference between deoxycholic acid 2 mg/cm² and placebo.
An adjustment for multiplicity was performed for the two co-primary endpoints. This was accounted for by using the larger of the two P-values in the Bonferroni-Holm scheme.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression analysis with treatment and Baseline CR-SMFRS value in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.83</ci_lower_limit>
            <ci_upper_limit>5.36</ci_upper_limit>
            <estimate_desc>The odds ratio was based on a logistic regression model adjusted for the Baseline score. Odds ratios &gt;1 indicate a positive treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a CR-SMFRS 2-grade Response</title>
        <description>A CR-SMFRS 2-grade response is defined as at least a 2-point improvement (i.e. 2-point reduction) from Baseline 12 weeks after the last treatment.
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <population>Intent-to-treat population; LOCF method was used to impute missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid Injection 1 mg/cm²</title>
            <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
          <group group_id="O2">
            <title>Deoxycholic Acid Injection 2 mg/cm²</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a CR-SMFRS 2-grade Response</title>
          <description>A CR-SMFRS 2-grade response is defined as at least a 2-point improvement (i.e. 2-point reduction) from Baseline 12 weeks after the last treatment.
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.</description>
          <population>Intent-to-treat population; LOCF method was used to impute missing data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="9.0"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression analysis with treatment and Baseline CR-SMFRS value in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.48</ci_lower_limit>
            <ci_upper_limit>92.67</ci_upper_limit>
            <estimate_desc>Odds ratio was based on a logistic regression model adjusted for the Baseline score. Odds ratios &gt;1 indicate a positive treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression analysis with treatment and Baseline CR-SMFRS value in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>91.24</ci_upper_limit>
            <estimate_desc>Odds ratio was based on a logistic regression model adjusted for the Baseline score. Odds ratios &gt;1 indicate a positive treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Subject Self Rating Scale (SSRS) Response</title>
        <description>A SSRS response is defined as an SSRS score that is 4 or greater 12 weeks after the last treatment.
The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <population>Intent-to-treat population; LOCF method was used to impute missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid Injection 1 mg/cm²</title>
            <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
          <group group_id="O2">
            <title>Deoxycholic Acid Injection 2 mg/cm²</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Subject Self Rating Scale (SSRS) Response</title>
          <description>A SSRS response is defined as an SSRS score that is 4 or greater 12 weeks after the last treatment.
The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.</description>
          <population>Intent-to-treat population; LOCF method was used to impute missing data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3"/>
                    <measurement group_id="O2" value="64.8"/>
                    <measurement group_id="O3" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was there was no difference between deoxycholic acid 1 mg/cm² and placebo.
An adjustment for multiplicity was performed for the two co-primary endpoints. This was accounted for by using the larger of the two P-values in the Bonferroni-Holm scheme.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression analysis with treatment and Baseline SSRS value in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.06</ci_lower_limit>
            <ci_upper_limit>9.44</ci_upper_limit>
            <estimate_desc>Odds ratio was based on a logistic regression model adjusted for Baseline score. Odds ratios &gt;1 indicate a positive treatment effect.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was there was no difference between deoxycholic acid 2 mg/cm² and placebo.
An adjustment for multiplicity was performed for the two co-primary endpoints. This was accounted for by using the larger of the two P-values in the Bonferroni-Holm scheme.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression analysis with treatment and Baseline SSRS value in the model</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.65</ci_lower_limit>
            <ci_upper_limit>8.04</ci_upper_limit>
            <estimate_desc>Odds ratio was based on a logistic regression model adjusted for Baseline score. Odds ratios &gt;1 indicate a positive treatment effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CR-SMFRS Score</title>
        <description>The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.
A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <population>Intent-to-treat population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid Injection 1 mg/cm²</title>
            <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
          <group group_id="O2">
            <title>Deoxycholic Acid Injection 2 mg/cm²</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CR-SMFRS Score</title>
          <description>The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.
A negative change from Baseline indicates improvement.</description>
          <population>Intent-to-treat population with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.64"/>
                    <measurement group_id="O2" value="-0.8" spread="0.61"/>
                    <measurement group_id="O3" value="-0.4" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Repeated Measures</method>
            <method_desc>The model included the fixed effect factors visit and treatment, the visit*treatment interaction, and the Baseline CR-SMFRS values as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Repeated Measures</method>
            <method_desc>The model included the fixed effect factors visit and treatment, the visit*treatment interaction, and the baseline CR-SMFRS values as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SSRS Scores</title>
        <description>The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.
A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <population>Intent-to-treat population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid Injection 1 mg/cm²</title>
            <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
          <group group_id="O2">
            <title>Deoxycholic Acid Injection 2 mg/cm²</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SSRS Scores</title>
          <description>The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.
A positive change from Baseline indicates improvement.</description>
          <population>Intent-to-treat population with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.61"/>
                    <measurement group_id="O2" value="2.9" spread="1.53"/>
                    <measurement group_id="O3" value="1.5" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes the fixed effect factor treatment and the Baseline values as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes the fixed effect factor treatment and the Baseline values as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Submental Fat Thickness</title>
        <description>Submental thickness was measured using caliper devices.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <population>Intent-to-treat population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid Injection 1 mg/cm²</title>
            <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
          <group group_id="O2">
            <title>Deoxycholic Acid Injection 2 mg/cm²</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Submental Fat Thickness</title>
          <description>Submental thickness was measured using caliper devices.</description>
          <population>Intent-to-treat population with available data</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="3.67"/>
                    <measurement group_id="O2" value="-3.8" spread="4.41"/>
                    <measurement group_id="O3" value="-2.5" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>Mixed Models Repeated Measures</method>
            <method_desc>The model includes the fixed effect factors visit and treatment, the visit*treatment interaction, and the Baseline values as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.72</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Mixed Models Repeated Measures</method>
            <method_desc>The model includes the fixed effect factors visit and treatment, the visit*treatment interaction, and the Baseline values as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)</title>
        <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you currently have under your chin?&quot; answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. Improvement is defined as any decrease in score and worsened as any increase in score.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <population>Intent-to-treat population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid Injection 1 mg/cm²</title>
            <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
          <group group_id="O2">
            <title>Deoxycholic Acid Injection 2 mg/cm²</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)</title>
          <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you currently have under your chin?&quot; answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. Improvement is defined as any decrease in score and worsened as any increase in score.</description>
          <population>Intent-to-treat population with available data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9"/>
                    <measurement group_id="O2" value="67.3"/>
                    <measurement group_id="O3" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                    <measurement group_id="O2" value="30.9"/>
                    <measurement group_id="O3" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Pearson's chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Pearson's chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)</title>
        <description>The PR-SMFIS assesses the impact of submental fat on self-perception of 6 characteristics related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Self-rating of Attractiveness</title>
        <description>Self-rating of attractiveness assesses aspects of appearance from the participant's perspective by a series of 6 questions:
How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?&quot; Each question was answered on a scale from 1 to 9 where 1 = Not at all attractive, 5 = Neither attractive nor unattractive and 9 = Extremely attractive.
A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <population>Intent-to-treat population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid Injection 1 mg/cm²</title>
            <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
          <group group_id="O2">
            <title>Deoxycholic Acid Injection 2 mg/cm²</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Self-rating of Attractiveness</title>
          <description>Self-rating of attractiveness assesses aspects of appearance from the participant's perspective by a series of 6 questions:
How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?&quot; Each question was answered on a scale from 1 to 9 where 1 = Not at all attractive, 5 = Neither attractive nor unattractive and 9 = Extremely attractive.
A positive change from Baseline indicates improvement.</description>
          <population>Intent-to-treat population with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.37"/>
                    <measurement group_id="O2" value="0.6" spread="1.29"/>
                    <measurement group_id="O3" value="0.3" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chin / Neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.36"/>
                    <measurement group_id="O2" value="2.1" spread="2.00"/>
                    <measurement group_id="O3" value="0.9" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.18"/>
                    <measurement group_id="O2" value="0.3" spread="1.55"/>
                    <measurement group_id="O3" value="0.3" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.53"/>
                    <measurement group_id="O2" value="0.4" spread="1.41"/>
                    <measurement group_id="O3" value="0.5" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.02"/>
                    <measurement group_id="O2" value="0.3" spread="1.25"/>
                    <measurement group_id="O3" value="0.1" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Entire Face</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.21"/>
                    <measurement group_id="O2" value="0.6" spread="1.12"/>
                    <measurement group_id="O3" value="0.4" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Derriford Appearance Scale 24 (DAS24)</title>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Image Quality of Life Inventory (BIQLI)</title>
        <time_frame>Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)</time_frame>
        <posting_date>01/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug until 12 weeks after the last dose (up to 24 weeks after first treatment).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Deoxycholic Acid Injection 1 mg/cm²</title>
          <description>Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
        </group>
        <group group_id="E2">
          <title>Deoxycholic Acid Injection 2 mg/cm²</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Nerve Damage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Oedema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Injection Site Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure</name_or_title>
      <organization>Kythera</organization>
      <email>clinical_trials@kythera.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

